Follow CGSP on Social Media

Listen to the CGSP Podcast

In a Potentially Troubling Development for Africa, Sinovac Did Not Perform Well in Early Test Against Omicron Variant

A healthcare worker holds up a SINOVAC Covid-19 vaccine before administering it on a minor during the Numolux/SINOVAC Peadiatric Covid-19 Vaccine Clinical Trial at the University in Pretoria, on September 10, 2021. Phill Magakoe / AFP

Researchers at the University of Hong Kong (HKU) found that people inoculated with two doses of Sinovac’s COVID-19 vaccine did not produce sufficient detectable levels of antibodies needed to fend off the new highly-infectious Omicron variant.

A third injection did generate some antibodies but researchers cautioned that it is still too early to tell if the extra booster would be enough to prevent infection.

Lead the Conversation on China

Subscribe Today to Get Full Access to The China-Global South Project

Check Out Everything You'll Get With Your Subscription

The China-Global South Daily Brief delivered to your inbox at 6AM Washington time

Full access to exclusive news and analysis from editors based in the Global South

Transcripts of CGSP’s twice-weekly podcasts

Students and teachers with a valid .edu email address are eligible for a 50% discount off monthly or yearly subscriptions. Email us to receive a discount code.

What is The China-Global South Project?

Independent

The China-Global South Project is passionately independent, non-partisan and does not advocate for any country, company or culture.

News

A carefully curated selection of the day’s most important China-Global South stories. Updated 24 hours a day by human editors. No bots, no algorithms.

Analysis

Diverse, often unconventional insights from scholars, analysts, journalists and a variety of stakeholders in the China-Global South discourse.

Networking

A unique professional network of China-Africa scholars, analysts, journalists and other practioners from around the world.